11.01.2016 • NewsElaine BurridgeSanofiMannkind

Sanofi Gives Back Insulin Drug to MannKind

Sanofi has handed back rights to the inhaled insulin treatment Afrezza to US drug development company MannKind.

Sales of Afrezza, which launched in the US in February last year, have been disappointing. A Sanofi spokesman told the news agency Reuters that the product never met even modest expectations while costs were projected to remain very high for a significant period.

MannKind said the companies would promptly start discussions to secure a “smooth and orderly transition in the development and commercialization of Afrezza from Sanofi over the next 90-180 days.”

In any event, termination of the license agreement would be effective no later than six months from the date of Sanofi’s notice, or Jul. 4, 2016.

The company added that it was reviewing its strategic options for Afrezza. Industry observers believe that MannKind could face bankruptcy as a result of Sanofi’s decision.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.